2. Neuronal Signaling MAPK/ERK Pathway Apoptosis Immunology/Inflammation Metabolic Enzyme/Protease
  3. Amyloid-β JNK MDM-2/p53 Caspase SOD Glutathione Peroxidase NO Synthase
  4. Pseudoginsenoside F11

Pseudoginsenoside F11  (Synonyms: Ginsenoside A1)

Cat. No.: HY-N0541 Purity: 99.87%
COA
SDS
Handling Instructions Technical Support

Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of Aβ1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity.

For research use only. We do not sell to patients.

Pseudoginsenoside F11

Pseudoginsenoside F11 Chemical Structure

CAS No. : 69884-00-0

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Pseudoginsenoside F11:

Pseudoginsenoside F11 Related Antibodies

Top Publications Citing Use of Products

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Glutathione Peroxidase Isoform Specific Products:

View All Isoforms
GPX1 GPX4

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of Aβ1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity[1][2][3].

IC50 & Target[1]

JNK2

 

Caspase 3

 

In Vitro

Pseudoginsenoside F11 (10-100 μM; 2 h pre-treatment; 0-24 h OGD/R) protects cultured primary cortical neurons against OGD/R-induced injury by increasing cell viability, restoring neurite structure, maintaining calcium homeostasis, replenishing ATP levels, inhibiting μ-Calpain-mediated α-Fodrin cleavage, reversing deficits in NMDA receptor subunits/PSD95/nNOS, and alleviating endoplasmic reticulum stress, with the most robust effects observed at 100 μM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pseudoginsenoside F11 Related Antibodies
In Vivo

Pseudoginsenoside F11 (0.32-8 mg/kg; p.o.; daily; 15 days) significantly mitigates Aβ1-42-induced learning and memory impairment in KM mice, with the 8 mg/kg dose showing robust improvement across both Morris water maze and step-through tests[1].
Pseudoginsenoside F11 (8 mg/kg; p.o.; daily; 28 days) significantly improves learning and memory deficits in APP/PS1 mice, mediated by reduced amyloidogenesis, restored antioxidant function, reduced neuronal apoptosis, and improved neuronal histopathology[1].
Pseudoginsenoside F11 (12 mg/kg; i.v.; single dose, 0-8 hours post-reperfusion; 3-12 mg/kg; i.v. initial dose, i.p. daily; 14 days) produces dose-dependent neuroprotection in transient cerebral ischemia-reperfusion injured rats, reducing acute brain damage by up to 48.1% infarct volume reduction with a 4-hour therapeutic window, improving long-term survival by 13.6% at 12 mg/kg, and restoring motor function and neuronal health via repression of sustained calcium overload[2].
Pseudoginsenoside F11 (4-8 mg/kg; p.o.; two times at 4-hour intervals) significantly protects against methamphetamine-induced behavioral neurotoxicities (anxiety, despair, memory impairment) and partially reverses methamphetamine-induced brain dopamine depletion in mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: KM mice (male, 6-8 week-old, Alzheimer's disease model via intracerebroventricular injection of 410 pmol Aβ1-42)[1]
Dosage: 0.32 mg/kg; 1.6 mg/kg; 8 mg/kg
Administration: p.o.; daily; 15 days
Result: Significantly reduced Aβ1-42-induced increases in escape latency (p < 0.05 on days 3, 4, and 5 of place navigation testing) and escape distance (p < 0.05 on day 5 of place navigation testing) at 8 mg/kg.
Restored reduced time spent in the target quadrant (p = 0.004) in the Morris water maze probe test and blocked reduced step-through latency in the retention trial (p = 0.026) at 8 mg/kg.
Reduced escape latency on day 3 of place navigation testing (p < 0.05) and restored reduced time spent in the target quadrant (p = 0.011) in the probe test at 1.6 mg/kg.
Showed no significant effects on swim velocity across all doses.
Animal Model: Swiss mice (male, 7-week-old, 20-22 g, methamphetamine-induced neurotoxicity model)[3]
Dosage: 4 mg/kg; 8 mg/kg
Administration: p.o.; two times at 4-hour intervals
Result: Shortened methamphetamine-induced prolonged time spent in the dark box in the light-dark box task.
Reversed methamphetamine-induced prolonged immobility time in the forced swimming task.
Shortened methamphetamine-induced prolonged latency to find food and reduced the number of errors in the appetitively motivated T-maze task.
Shortened methamphetamine-induced prolonged escape latency to locate the hidden platform across test days in the Morris water maze task.
Partially but significantly antagonized the methamphetamine-induced decrease in brain dopamine (DA) content, with a 23.22% recovery of DA levels.
Showed no significant effect on methamphetamine-induced decreases in 3,4-dihydroxyphenacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindoacetic acid (5-HIAA), or 5-hydroxytryptamine (5-HT) contents.
Affected neither swimming ability, spontaneous behavior, nor baseline levels of brain monoamines and their metabolites in non-methamphetamine-treated mice.
Molecular Weight

801.01

Formula

C42H72O14
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

C[C@@]([C@@]12C)(C[C@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]3O)([H])[C@@H]3O[C@@](O[C@@H](C)[C@H](O)[C@H]4O)([H])[C@@H]4O)[C@@]5([H])C6(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@]7(O[C@@H](C(C)(O)C)CC7)C)([H])CC2)([H])[C@]5(CC[C@@H]6O)C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (62.42 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 0.67 mg/mL (0.84 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2484 mL 6.2421 mL 12.4842 mL
5 mM 0.2497 mL 1.2484 mL 2.4968 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (3.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.87%

SDS (393 KB)

COA (259 KB) HNMR (308 KB) RP-HPLC (208 KB) MS (70 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.2484 mL 6.2421 mL 12.4842 mL 31.2106 mL
5 mM 0.2497 mL 1.2484 mL 2.4968 mL 6.2421 mL
10 mM 0.1248 mL 0.6242 mL 1.2484 mL 3.1211 mL
15 mM 0.0832 mL 0.4161 mL 0.8323 mL 2.0807 mL
20 mM 0.0624 mL 0.3121 mL 0.6242 mL 1.5605 mL
25 mM 0.0499 mL 0.2497 mL 0.4994 mL 1.2484 mL
30 mM 0.0416 mL 0.2081 mL 0.4161 mL 1.0404 mL
40 mM 0.0312 mL 0.1561 mL 0.3121 mL 0.7803 mL
50 mM 0.0250 mL 0.1248 mL 0.2497 mL 0.6242 mL
60 mM 0.0208 mL 0.1040 mL 0.2081 mL 0.5202 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pseudoginsenoside F11 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pseudoginsenoside F1169884-00-0Ginsenoside A1Pseudoginsenoside F 11Pseudoginsenoside F-11Ginsenoside A 1Ginsenoside A-1Amyloid-βJNKMDM-2/p53CaspaseSODGlutathione PeroxidaseNO Synthaseβ-amyloid peptideAβAbetac-Jun N-terminal kinaseSuperoxide DismutaseNitric oxide synthasesNOSAβ1-40cortexsuperoxide dismutasehippocampuscleaved caspase 3μ-Calpainβ-amyloid precursor proteinglutathione peroxidaseJNK 2p53Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Pseudoginsenoside F11
Cat. No.:
HY-N0541
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.